Company Overview


Celsee, Inc., a privately held company in the Ann Arbor, Michigan area, is breaking through the traditional barriers of single-cell analysis and delivering clinical-grade technology designed to support the life sciences revolution and precision medicine. Based on a gentle, gravity-induced, micro-well isolation technique, the patented technology forms the foundation for a scalable and flexible single-cell analysis platform that makes more experiments feasible. Celsee’s first product, the Genesis system, enables scientists to analyze and interpret cellular behavior and collect previously inaccessible information for improved results in applications such as proteogenomics, next-generation sequencing, immune monitoring, and cell therapy.

Board of Directors

Jack Ball
Jack Ball is CEO and a board member at Solulink, Inc., President of Tyball Associates, LLC, and Executive Chairman of the Board at Aquaro Histology, Inc. In addition he serves on the board of directors of NanoCellect, Carterra, Swift Bioscience and DNA Software. Most recently he was CCO at Accuri Cytometers, which was sold to Becton Dickinson in March 2011. Prior to Accuri Cytometers, he was CEO of Amnis Corporation, and has also served as CCO for Molecular Probes, Inc. Prior to that he was with Orchid Biosciences as Sr. VP and General Manager and with Amersham Pharmacia Biotech Inc., where he rose to President for North America.
Kalyan Handique, Ph.D.
Kalyan Handique is President of Celsee and an experienced serial entrepreneur with deep domain knowledge in microfluidics and medical devices. Prior to joining Celsee, Dr. Handique was one of the founders of HandyLab; a molecular diagnostic start-up based in Ann Arbor, Michigan, that was successfully sold to Becton Dickinson in late 2009 in a highly publicized acquisition. Prior to HandyLab, he completed his Ph.D. in Bioengineering at the University of Michigan. In addition to his duties with Celsee, Dr. Handique serves as an advisor and board member to many other start-up companies in the Michigan Biotech Region.
John (Kip) Miller
John L. (Kip) Miller is co-founder of San Diego based Tonbo Biosciences, and currently serves as an independent board member at Biological Dynamics. An experienced life sciences executive and entrepreneur he has played an active role in the development and growth of leading life science companies; BD Biosciences, Invitrogen, and Life Technologies. Mr. Miller has built a strong background in senior executive leadership, M&A, and commercial operations and has developed extensive experience in the segments of research life sciences, genomics and diagnostics.
Roger Newton
Roger S. Newton, Ph.D., FAHA, FACN is the Founder, Board Director, and former President/CEO, Executive Chairman, and Chief Scientific Officer at Esperion Therapeutics. He is a Fellow of the American Heart Association and the American College of Nutrition, where he also serves as its President. Dr. Newton is also a Board Director on a number of life science companies including Celsee, Juventas Therapeutics, and FirstSense Medical Products.  He serves on several National Advisory Boards at the University of Michigan including the Life Science Institute, the Frankel Cardiovascular Center, and the Alfred Taubman Medical Research Institute. Dr. Newton is also an Executive-in- Residence at the Center for Positive Organizations at the University of Michigan Ross School of Business. Lastly, he has served on the Technical Advisory Board of Arboretum Ventures in Ann Arbor, MI since its founding in 2002.
John Stark
John Stark was appointed Chief Executive Officer of Celsee in 2017 to expand the company’s strategy, operations and commercial efforts. Before joining Celsee, John held a variety of executive level positions in the life sciences industry. Previous leadership roles include Senior Vice President of Global Applied Commercial Operations at Fluidigm and Vice President of Clinical Sequencing Commercial Operations at Thermo Fisher Scientific (formerly Life Technologies). Additionally, John was involved in assembling and scaling commercial organizations that experienced explosive growth in the genomics and sequencing markets. At Affymetrix he led the global pharma business unit and at Pacific Biosciences he established the initial commercial organization. John has also been in operational roles in R&D and manufacturing at Motorola and IEM. Through these unique roles, John brings the experience and vision for commercializing innovative technologies into mainstream application and clinical practice. John received a B.S. from Western Michigan University in Biomedical Sciences and a M.S. from Arizona State University in Biomedical Engineering.
Walt Young
Walt Young has been involved in a wide variety of start-ups over the past 15 years. Other, current life-science startups he is involved with include Solulink, Inc. and Swift Biosciences. Exits include Accuri Cytometers and ViroCyt.
Sign up for our newsletter and stay up to date.